Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Speedel board recommends acceptance of Novartis offer

This article was originally published in Scrip

Executive Summary

Speedel's board of directors has recommended that its shareholders accept the offer made by Novartisto acquire the company for CHF130 ($126) per share. Novartis bought 51.7% of the shares in Speedel in July, bringing the total amount of shares it owned to 61.4%, and subsequently began a mandatory tender offer to acquire the company. The offer, which was in the mid-third of analyst recommendations, is considerably higher than the average price of Speedel's shares for the 60 trading days before the announcement of the offer – CHF72.19 – and Novartis expects the full acquisition to cost CHF907 million (Scrip Online, July 10th, 2008).

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC003441

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel